The contribution of N4-acetylsulfadimethoxine (N4-AcSDM), a major metabolite of sulfadimethoxine (SDM ), to the serum protein binding and pharmacokinetic interactions between SDM and ketoprofen (KPF) was investigated in rabbits. When SDM and KPF were intravenously coadministered, KPF indirectly reduced the serum protein binding of SDM through the interaction of KPF with N4-AcSDM, and significantly increased the total body clearance (Cltot) and steady-state volume of distribution ( Vdss) of SDM. In addition, the co-administration of N4-AcSDM was found to increase Cltot and Vdss of SDM. These results indicate that N4-AcSDM contributes substantially to the serum protein binding and pharmacokinetic interactions between SDM and KPF in rabbits. Several investigators have demonstrated that a metabolite can contribute to drug-drug interaction.1-3) For example, when warfarin and chloral hydrate were co-administered, a major metabolite of chloral hydrate, trichloroacetic acid, reduced the serum protein binding of warfarin and enhanced its anti-coagulant activity.1) In addition, probenecid indirectly reduced the serum protein binding of sulfadimethoxine (SDM) through the interaction of probenecid with N4-acetylsulfadimethoxine (N4-AcSDM),2) a major metabolite of SDM.4) However, the contribution of metabolites to drug-drug interaction has not yet been fully examined. The purpose of the present study was to elucidate the contribution of N4-AcSDM to the serum protein binding and pharmacokinetic interactions between SDM and ketoprofen (KPF) in rabbits.
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Experimental

Materials
SDM was purchased from Daiichi Pharmaceutical Co., Tokyo. KPF was kindly supplied by Kaken Pharmaceutical Co., Tokyo. N4-AcSDM was synthesized from SDM by the method of Uno et al.5) All other chemicals were of reagent grade.
Animal Experiments Male albino rabbits weighing 2.5-3.5 kg were used in a cross-over design. An interval of at least 10 d was taken to minimize the residual or cumulative effect of the preceding dose. SDM at a dose of 50 mg/kg was administered intravenously as a bolus to rabbits. KPF or N4-AcSDM at a dose of 25 mg/kg was administered intravenously as a bolus immediately after SDM administration. The injections of SDM, KPF and N4-AcSDM were prepared by dissolving the drugs in saline solution containing the same molar amount of NaOH. Blood samples were collected from the ear vein. The blood was centrifuged at 3000 rpm for 15 min and the serum or plasma was separated.
Protein Binding Experiments -In vivo and in vitro protein binding experiments were carried out by means of the ultrafiltration method described previously.6) The in vivo protein binding of SDM was determined for the serum obtained at 2 h after intravenous bolus administration of SDM alone or in combination with KPF. The in vitro protein binding of SDM was determined for the serum prepared by the addition of SDM with or without KPF or N4-AcSDM.
Pharmacokinetic Analysis -The plasma SDM concentration data were analyzed by statistical moment analysis to obtain values for the total body clearance (Cltot) and steady-state volume of distribution ( Vdss) of SDM according to the following equation7): 
Results and Discussion
Serum Protein Binding Interaction The effect of KPF on the in vivo and in vitro bindings of SDM to rabbit serum was examined. As shown in Fig. 1 , KPF markedly reduced the in vivo binging of SDM to rabbit serum. On the other hand, KPF had little effect on the in vitro binding of SDM to rabbit serum (Fig. 2) . It is noteworthy that KPF reduces only the in vivo binding of SDM to rabbit serum.
Our previous paper2) showed that N4-AcSDM strongly displaces SDM from its protein binding sites. Since N4-AcSDM is the major metabolite of SDM in rabbits ,41 it may contribute to the in vivo protein binding interaction between SDM and KPF . As shown in Fig.  3 , the co-administration of KPF was found to increase the serum concentration of N4 -AcSDM at 2 h after intravenous bolus administration of SDM. This finding implies that KPF indirectly reduces the in vivo serum protein binding of SDM, by causing an increase in the Pharmacokinetic Interaction Figure 5 shows the time course of the plasma concentrations of SDM and N4-AcSDM after intravenous bolus administration of SDM alone or in combination with KPF. The coadministration of KPF markedly decreased the plasma concentration of SDM, while the coadministration of KPF markedly increased the plasma concentration of N4-AcSDM. In addition, the pharmacokinetic parameters were derived from the SDM plasma concentration data. As shown in Table I , the co-administration of KPF significantly increased Cltot and Vdss of SDM. Recently, the displacement of one drug from its protein binding sites by another has been reported to induce increases in Cltot and/or Vdss of the drug.14,15) For example, Arimori et al. reported that penicillins displace phenytoin from its protein binding sites, and significantly increase Cltot and Vdss of phenytoin.1 5 ) Thus, the increases in Ow, and Vdss of SDM induced by KPF may be explained on the basis of the displacement of SDM from its protein binding sites by N4-AcSDM.
To confirm the contribution of N4-AcSDM to the pharmacokinetic interaction between to Rabbits SDM and KPF, we examined whether the co-administration of N4-AcSDM decreases the plasma concentration of SDM after intravenous bolus administration. As expected, the coadministration of N4-AcSDM markedly decreased the plasma concentration of SDM (Fig. 6) , resulting in significant increases in Cltot, and Vdss of SDM (Table II) . Interestingly, the coadministration of N4-AcSDM, in contrast to that of KPF, caused a marked decrease in the plasma concentration of SDM at the early stage (distribution phase) after intravenous bolus administration. These observations indicate that N4-AcSDM contributes to the pharmacokinetic interaction between SDM and KPF in rabbits. 
